Biocartis Group NV provided financial guidance for the fiscal year 2023. Building on the strong performance of 2022, the company expects to take a next significant step towards operating profitability, with: product related revenues of between EUR 55 million and EUR 60 million, reflecting growth of 25%-35% when excluding sales of SARS-CoV-2 tests that are expected to further decrease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.08M | |
+73.17% | 12.38B | |
-18.74% | 7.92B | |
+16.15% | 7.2B | |
+4.81% | 5.84B | |
+5.99% | 5.07B | |
+27.07% | 4.53B | |
-21.67% | 3.88B | |
-40.82% | 2.23B | |
+1.49% | 2.02B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group Nv Provides Financial Guidance for the Fiscal Year 2023